MedPath

Lymph Node Radiation Therapy in Patients With Stage I, Stage II, or Stage III Breast Cancer That Has Been Surgically Removed

Phase 3
Conditions
Breast Cancer
Registration Number
NCT00002851
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Radiation therapy may kill any tumor cells remaining after surgery.

PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to no further therapy in treating women with stage I, stage II, or stage III breast cancer that has been surgically removed.

Detailed Description

OBJECTIVES:

* Compare the effect of irradiation of the homolateral internal mammary and medial supraclavicular lymph node chains vs no further therapy on survival, disease-free survival, metastasis-free survival, and cause of death in women with resected stage I/II/III breast cancer.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by participating institution, tumor location, type of prior breast surgery, pathologic T and N stage, menopausal status, and time sequence of radiotherapy and adjuvant chemotherapy. Patients are randomized to 1 of 2 arms.

* Arm I: Patients receive no nodal irradiation.

* Arm II: Patients receive irradiation of the internal mammary and medial supraclavicular lymph node chains delivered at 1 fraction per day, 5 sessions per week, for a total of 25 fractions over 5 weeks. Radiotherapy must begin no later than 8 weeks after surgery. If adjuvant chemotherapy is given, radiotherapy begins within 6 weeks after the last course of chemotherapy and within 8 months after surgery.

Patients are followed at least yearly after randomization for up to 20 years.

PROJECTED ACCRUAL: A total of 4,000 patients will be accrued for this study within 4 years.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
4000
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (48)

Ziekenhuis Network Antwerpen Middelheim

🇧🇪

Antwerp, Belgium

Cliniques Universitaires Saint-Luc

🇧🇪

Brussels, Belgium

Hopital de Jolimont

🇧🇪

Haine Saint Paul, Belgium

Cazk Groeninghe - Campus Maria's Voorzienigheid

🇧🇪

Kortrijk, Belgium

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Algemeen Ziekenhuis Sint-Augustinus

🇧🇪

Wilrijk, Belgium

Institute of Oncology - Clinical Center University of Sarajevo

🇧🇦

Sarajevo, Bosnia and Herzegovina

Instituto de Radiomedicina

🇨🇱

Santiago, Chile

Clinica Alemana

🇨🇱

Santiago, Chile

CHR de Besancon - Hopital Jean Minjoz

🇫🇷

Besancon, France

Scroll for more (38 remaining)
Ziekenhuis Network Antwerpen Middelheim
🇧🇪Antwerp, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.